Tagged with Pharma

India A successful commercial leader, Annaswamy Vaidheesh, president of OPPI, VP South Asia and managing director at GSK India, talks about the tremendous work that the local affiliate is doing in the country in making innovative products available to patients and their recent GBP 100 million investment in manufacturing. Can you…

Canada Moving into the position of National Pharma & Life Sciences Leader, PwC’s Rami El-Cheikh announces the firm’s plan to introduce the comprehensive Pharma Advisory Services currently existing in the US into Canada, including enterprise and function-specific service expertise. He further identifies areas of potential growth in healthcare-related industries, putting forward…

India A strong supporter of public-private partnerships, MSD’s managing director in India, Vivek Kamath, explains how the company’s collaborative approach is the key to enhancing their reputation, improving patient outcomes and tackling unmet medical needs in India.   Mr. Kamath, you have worked for MSD for over four years and you…

Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…

India Ashok Battacharya, executive director of the Indian affiliate of Takeda Pharmaceuticals, with 38 years experience in global Ppharmaceutical MNCs, discusses the top-notch reputation that Takeda has among physicians and patients and how the company is working towards making Takeda’s innovative medications available to Indian Patients. Can you give our international…

India Think global, act local! This is the Novartis business approach in India. A great believer in stakeholder collaboration, Jawed Zia, country president of Novartis India, explains how co-marketing deals with big names like Cipla and Lupin allow patients in every corner of the country to benefit from the company’s breakthrough…

Estonia Kadri Maegi-Lehtsi, general manager of Roche Pharmaceuticals Estonia, discusses the company’s established footprint in the Estonian market and their mission to give back to the Estonian society not only by providing innovative and highly needed medicines, but also through awareness and lifestyle campaigns. In Estonia, Roche focuses on marketing and…

Poland Cezary Kilczewski, president and founder of Medicofarma, a Polish CMO, discusses the company’s recent upgrades to double production capacity and the move into R&D operations as well as the dynamics of the possible CMO threat from cheaper nations in the east. He also highlights the strong positing of the company…

Baltics Juris Hmelnickis PhD, Chairman of the Board of JSC Kalceks, explains the story and the evolution of the company in Latvia, its key products in the CNS therapeutic area and how they were able to piggyback on the established footprint of their mother company, JSC Grindeks, to launch products in…

Poland Andrzej Schonert, CEO of Synoptis Industrial, discusses the intricacies of the Polish market and the requirement to move into niche areas, mainly in Rx, to concentrate their pharmaceutical offering to pharmacists, and in the future, hospitals. Furthermore, he highlights the company’s CMO activities and services to assist foreign players to…

Baltics Rauls Velins, Roche’s general manager for Latvia, introduces the company’s longstanding commitment to the Latvian market, Roche’s role in helping facilitate Latvia’s new National Cancer Plan, and the potential for personalized medicine across the Baltics. Could you please start by introducing Roche in Latvia and the strategic significance of the…

Baltics Kuuno Vaher, market access director Baltics and country lead of AstraZeneca Estonia, discusses the liberal attitude towards innovative and highly needed medicines of Estonian regulators and the crucial importance of closer collaboration with payers, which has led the thriving affiliate to have its portfolio reimbursed in the country. Can you…